Generation Bio Co., a biotechnology company focused on T cell-driven autoimmune diseases, reported a net loss of $20.9 million for the quarter ended June 30, 2025, compared to a net loss of $20.4 million in the same period in 2024. General and administrative expenses decreased to $7.7 million from $9.5 million year-over-year. The company's cash balance stood at $141.4 million as of June 30, 2025. In a significant operational update, Generation Bio entered a memorandum of understanding to settle a litigation case with the landlord of a Waltham, MA facility. This settlement involves a lump-sum payment of $31 million and will extinguish a lease liability of $58 million in the third quarter of 2025. Additionally, Generation Bio is undergoing a strategic restructuring that will result in a 90% workforce reduction, including its research and development organization, as part of a review process to explore strategic alternatives. The company recently announced new data on its cell-targeted lipid nanoparticle system, demonstrating successful siRNA delivery to T cells in non-human primates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.